Literature DB >> 19945027

Non-functioning pituitary adenomas.

Yona Greenman1, Naftali Stern.   

Abstract

Non-functioning pituitary tumours are mostly of gonadotroph cell origin and are devoid of humoral hypersecretory syndromes. They are usually large at the time of diagnosis, commonly presenting with headaches, visual field defects and hypopituitarism. Trans-sphenoidal surgery remains the treatment of choice for rapid decompression of neighbouring structures, often bringing to normalisation or improvement of visual and pituitary function. The management of patients with postoperative residual tumours is still a matter of debate and may include observation alone, the use of dopamine agonists or radiation therapy. There are no controlled or comparative studies of the available therapeutic options; therefore, recommendations are not evidence based. Patients need long-term follow-up for the detection and treatment of hypopituitarism, visual dysfunction and tumour growth that may develop over time.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945027     DOI: 10.1016/j.beem.2009.05.005

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  45 in total

1.  Isolated sixth cranial nerve palsy as the presenting symptom of a rapidly expanding ACTH positive pituitary adenoma: a case report.

Authors:  Norman Saffra; Elizabeth Kaplow; Irina Mikolaenko; Alice Kim; Benjamin Rubin; Jafar Jafar
Journal:  BMC Ophthalmol       Date:  2011-01-27       Impact factor: 2.209

2.  Differential DNA methylome profiling of nonfunctioning pituitary adenomas suggesting tumour invasion is correlated with cell adhesion.

Authors:  Ye Gu; Xinyao Zhou; Fan Hu; Yong Yu; Tao Xie; Yuying Huang; Xinzhi Zhao; Xiaobiao Zhang
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

3.  Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas.

Authors:  Orsalia Alexopoulou; Valérie Everard; Martine Etoa; Edward Fomekong; Stéphane Gaillard; Fabrice Parker; Christian Raftopoulos; Philippe Chanson; Dominique Maiter
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

Review 4.  Optimal management of non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

5.  Commentary on "expression of dopamine 2 receptor subtypes mRNA in clinically nonfunctioning pituitary adenomas".

Authors:  Andrea Salmaggi; Sandro Lodrini
Journal:  Neurol Sci       Date:  2011-08-06       Impact factor: 3.307

6.  Giant pituitary adenoma.

Authors:  Rodrigo Nazário Leão; José Tiago Baptista; José Vaz Ribeiro
Journal:  BMJ Case Rep       Date:  2014-11-05

Review 7.  Subclinical hyperfunctioning pituitary adenomas: the silent tumors.

Authors:  Odelia Cooper; Shlomo Melmed
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2012-05-22       Impact factor: 4.690

8.  Expression of the pituitary stem/progenitor marker GFRα2 in human pituitary adenomas and normal pituitary.

Authors:  Nestoras Mathioudakis; Ram Sundaresh; Alexandra Larsen; William Ruff; Jennifer Schiller; Hugo Guerrero-Cázares; Peter Burger; Roberto Salvatori; Alfredo Quiñones-Hinojosa
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

Review 9.  Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.

Authors:  Georgia Ntali; John A Wass
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

10.  Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

Authors:  James A Balogun; Eric Monsalves; Kyle Juraschka; Kashif Parvez; Walter Kucharczyk; Ozgur Mete; Fred Gentili; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.